BofA analyst Jason Zemansky raised the firm’s price target on Rocket Pharmaceuticals (RCKT) to $9 from $8 and keeps a Buy rating on the shares. Following Kresladi’s approval, the firm is adjusting sales estimates to reflect updated timelines and its model for Q4 updates, telling investors it views the stock’s negative reaction after approval as “surprising” given that Rocket’s call to discuss Kresladi’s approval didn’t provide many new updates. However, the firm acknowledges details around timelines and the lack of pricing commentary “may have disappointed,” the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Balancing Early Gene Therapy Validation Against Limited Near-Term Revenue and Pipeline Risk: Rationale for Maintaining a Hold on Rocket
- Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink
- PRV reception could net Rocket $100M-$200M, says LifeSci Capital
- Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush
- Rocket Pharmaceuticals: FDA Validation, Non-Dilutive Funding Catalyst, and Pipeline De-Risking Support Buy Rating